BioBots is empowering people to build with life. We are helping design and engineer biology to cure disease, eliminate the organ waiting list, revert climate change, and live on other planets. Our first product is a 3D bioprinter.
Our goal is to get the technology stacked behind that, in such a way that with these tools the interface for biology is no longer manual, it’s digital. What the PC did for computing, the BioBot can do for bioprinting and biology.
The concept of BioBots starts simple enough: a 3-D printer. We have written about 3-D printers here at Equities many times. However, we have never seen them like this. BioBots 3-D printer prints human cells. You may wonder what the market is for something like this, but think about organ donor wait times—a liver donor patient may wait close to five years! BioBots has the solution.
Founded in 2014, BioBots has taken in just $1.55 million in funding to develop the BioBot 1, a high resolution desktop 3D bioprinter that builds functional three dimensional living tissue. The BioBot 1 is the first desktop 3D bioprinter with a measurement of only 12 inches cubed.
When we last saw BioBots, company CEO Danny Cabrera took to the Disrupt stage to pitch his 3D printer for living cells to our panel of judges in the Startup Battlefield at Disrupt NY 2015. Cabrera showed off his company’s debut 3D bioprinter, and actually printed out a living 3D model of Vincent Van Gogh’s ear.
BioBots is a recently formed 3D bioprinting company that uses 3D printing technology to print living tissues into any shape. Measured at just 12 inches squared, this little desktop bioprinter has numerous applications depending on the type of Bio-Ink used which consist of different mixtures of cells and bio-compatible materials.
Danny Cabrera and Ricky Solorzano, co-founders of BioBots, were both named to the 30 Under 30 List in Manufacturing & Industry, credited with ushering in a new era in manufacturing.
We're making bioprinting as easy as possible. Anyone currently working in a lab doing 2D tissue culture has the background to effectively use a BioBot 1 3D bioprinter to fabricate 3D living tissues that are better mimics of the human body.
American start-up BioBots is working on making the printing of living tissue easier and cheaper by combining the ability of high-end tissue fabrication (often requiring large and expensive machinery in the $100,000 range) with inexpensive desktop 3D printing equipment.
With the launch of their first commercial 3D printer in the market, Philadelphia-based startup Biobots is making it possible to literally print human tissue. The Biobot 1 is an affordable machine – $10,000 – and is currently being used in over 50 labs around the world. The endgame is the stuff of science fiction books: being able to print complex structures such as functioning, live organs, and tissue that will forever end the need to test on animals and even humans.
U.S. biotech startup BioBots sits at the intersection between computer science and chemistry. Its debut product, a desktop 3D printer for biomaterials, which was just demoed on stage at TechCrunch Disrupt NY — printing Van Gogh’s ear in replica, no less — combines hardware, software and wetware.
3D bioprinting technology startup, BioBots, is seeking to disrupt the nascent field of bioprinting with its new printer for 3D living tissue creation.
With more affordable bioprinters like BioBots, the technology becomes more democratized and research developments can happen faster. Bioprinting is one of the most intriguing areas of the 3D printing industry, and the next decade will be exciting as technologists and physicians team up to figure out how to effectively 3D print working body parts.
Danny graduated from University of Pennsylvania with B.S. in Computational Biology, where he focused on the development of technologies that could manipulate and evaluate biological structures. He won the iGEM Grand Prize and the Best New Measurement Approach for North America while pursuing his academic passion.
During his undergraduate education at the University of Pennsylvania, Ricardo dedicated himself to engineering biological tissues in new and creative ways. While he researched and created the first version of the BioBots printer in his dorm room, he was also busy writing 6 published papers in the field and winning academic awards across the university.
As director of the Wake Forest Institute for Regenerative Medicine, Dr. Anthony Atala is a proven and well renowned thought leader in the field of biological engineer. Dr. Atala’s work was listed as Time Magazine’s top 10 medical breakthroughs of the year, and as Discover Magazine`s Number 1 Top Science Story of the Year in the field of medicine in 2007. In 2009 Dr. Atala was featured in U.S. News & World Report as one of 14 Pioneers of Medical Progress in the 21st Century, and his work in 2010 was listed by Smithsonian Magazine as one of 40 things to know about the next 40 years.